Anti-CD19(CVID3/429), Biotin conjugate, 0.1mg/mL

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms. Primary antibodies are available purified, or with a selection of fluorescent CF(R) Dyes and other labels. CF(R) Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF(R)405S and CF(R)405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors. Concentration: 0.1 mg/mL Storage buffer: PBS, 0.1% BSA, 0.05% azide